AstraZeneca: new failure for Imfinzi for lung cancer
(CercleFinance.com) - On Wednesday AstraZeneca announced that the combination of two of its drugs failed to reach the primary endpoint of a phase III trial for advanced stage lung cancer.
The final results of the "Neptune" trial showed that Imfinzi (durvalumab) coupled with tremelimumab failed to improve the overall survival of patients with stage 4 non-small cell lung cancer compared with chemotherapy alone.
The primary analysis population was patients with a high tumour mutational burden (TMB), the pharmaceutical group said.
Despite these results, the AstraZeneca share is pretty flat in London today after the publication of these results, while the FTSE 100 index is up about 0.7%.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The final results of the "Neptune" trial showed that Imfinzi (durvalumab) coupled with tremelimumab failed to improve the overall survival of patients with stage 4 non-small cell lung cancer compared with chemotherapy alone.
The primary analysis population was patients with a high tumour mutational burden (TMB), the pharmaceutical group said.
Despite these results, the AstraZeneca share is pretty flat in London today after the publication of these results, while the FTSE 100 index is up about 0.7%.
Copyright (c) 2019 CercleFinance.com. All rights reserved.